Buprenorphine: New treatment of opioid addiction in primary care

Canadian Family Physician

Volumn 57, Issue 3, 2011, Pages 281-289

  Kahan, Meldon ^a,b   Srivastava, Anita ^b,c   Ordean, Alice ^a,b,d   Cirone, Sharon ^a  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Toronto Centre for Substance Use in Pregnancy   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; OXYCODONE; OXYCODONE PLUS PARACETAMOL;

CLINICAL TRIAL; CONSTIPATION; DETOXIFICATION; DRUG ABUSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; HUMAN; LOW BACK PAIN; MAINTENANCE DRUG DOSE; NAUSEA; OBSERVATIONAL STUDY; OPIATE ADDICTION; PHARMACIST; PRESCRIPTION; PRIMARY MEDICAL CARE; REVIEW; SEDATION; SIDE EFFECT; URINALYSIS; WITHDRAWAL SYNDROME;

BUPRENORPHINE; HUMANS; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE;

EID: 79953174941     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med 2004;5(1):59-65. (Pubitemid 38404445)
2. Sproule B, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician 2009;55:68-9.e1-5. Available from: www.cfp.ca/cgi/reprint/55/1/68. Accessed 2011 Jan 27.
3. Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ 2006;175(11):1385-7.
4. Dasgupta N, Kramer ED, Zalman MA, Carino S Jr, Smith MY, Haddox JD, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82(2):135-42. Epub 2005 Oct 19.
5. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health 2006;120(4):320-8. Epub 2006 Feb 14. (Pubitemid 43372702)
6. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004;13(Suppl 1):S17-28.
7. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2):146-50. (Pubitemid 46513484)
8. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004;13(Suppl 1):S42-66.
9. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):231-41. (Pubitemid 34457057)
10. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58. (Pubitemid 37064768)
11. Ortner R, Jagsch R, Schindler SD, Primorac A, Fischer G; General Practitioner Addiction Team. Buprenorphine maintenance: office-based treatment with addiction clinic support. Eur Addict Res 2004;10(3):105-11. (Pubitemid 39070098)
12. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998;105(2):100-5. (Pubitemid 28405231)
13. O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 1996;22(4):523-31. (Pubitemid 26361024)
14. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 2004;13(Suppl 1):S29-41.
15. Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst Abus 2002;23(4):245-54. (Pubitemid 37093047)
16. Vignau J, Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res 1998;4(Suppl 1):24-8. (Pubitemid 28478991)
17. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003;179(1):38-42. (Pubitemid 36896192)
18. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11(9):1-171, iii-iv.
19. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract 2005;55(511):139-46. (Pubitemid 40246929)
20. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28(4):321-9. (Pubitemid 40733141)
21. Alford DP, LaBelle CT, Richardson JM, O'Connell JJ, Hohl CA, Cheng DM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med 2007;22(2):171-6. (Pubitemid 47308806)
22. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J, et al. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003;71(3):295-302. (Pubitemid 38368580)
23. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002207.
24. Update in: Database Syst Rev 2004;(3):CD002207.
25. Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4):527-30. (Pubitemid 46941212)
26. Borron SW, Monier C, Risède P, Baud FJ. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002;21(11):599-605. (Pubitemid 36040802)
27. Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003;47(8):1031-3. (Pubitemid 37013780)
28. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285(1):45. (Pubitemid 32042714)
29. Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164(5):797-803. (Pubitemid 46808535)
30. Lintzeris N, Muhleisen P, Ritter A. Clinical guidelines: buprenorphine treatment of heroin dependence. Canberra, Australia: National Expert Advisory Committee on Illicit Drugs; 2001.
31. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(2 Suppl):S87-101.
32. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99(2):209-14. (Pubitemid 38250755)
33. Schuh KJ, Walsh SL, Stitzer ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 1999;145(2):162-74. (Pubitemid 29362014)
34. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70(2 Suppl):S59-77.
35. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(2 Suppl):S39-47.
36. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2000;2(6):519-26.
37. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007;93(9):1051-5. Epub 2007 Mar 7. (Pubitemid 47310981)
38. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167(22):2469-75. (Pubitemid 350254906)
39. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 2008;5(3):684-92. Epub 2007 Dec 18. (Pubitemid 351337896)
40. Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2007;32(2):131-9. Epub 2007 Oct 30.
41. Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006;83(2):163-8. Epub 2005 Dec 15. (Pubitemid 44218969)
42. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007;7:5.
43. Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006;26(3):274-83. (Pubitemid 43804619)
44. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79(1):1-10. (Pubitemid 41557119)
45. Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003;98(1):103-10. (Pubitemid 36044342)
46. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997;62(5):569-71. (Pubitemid 28214935)
47. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP), series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: US Department of Health and Human Services; 2004.
48. Jones HE. Practical considerations for clinical use of buprenorphine. Sci Pract Perspect 2004;2(2):4-20.
49. Wesson DR, Ling WJ. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2):253-9. (Pubitemid 36927370)
50. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009;24(2):226-32. Epub 2008 Dec 17.
51. Caldiero RM, Parran TV Jr, Adelman CL, Piche B. Inpatient initiation of buprenorphine maintenance vs detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict 2006;15(1):1-7. (Pubitemid 43207183)
52. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994;54(17):1215-28. (Pubitemid 24107403)
53. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl) 1998;136(3):217-25. (Pubitemid 28143170)
54. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61(2):173-81. (Pubitemid 32008531)
55. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 2004;73(3):219-26. (Pubitemid 38231033)
56. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2002;(2):CD002025.
57. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006;(2):CD002025.
58. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005;62(10):1157-64. (Pubitemid 41396941)
59. Brigham GS, Amass L, Winhusen T, Harrer JM, Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat 2007;32(4):349-56. (Pubitemid 46661120)
60. Kornør H, Waal H, Ali RL. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug Alcohol Rev 2006;25(2):123-30. (Pubitemid 43688726)
61. Kornør H, Waal H, Sandvik L. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status. Drug Alcohol Rev 2007;26(2):135-41.
62. Horspool MJ, Seivewright N, Armitage CJ, Mathers N. Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res 2008;14(4):179-85. Epub 2008 Jun 27.
63. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355(4):365-74. (Pubitemid 44127539)
64. Vignau J, Duhamel A, Catteau J, Legal G, Pho AH, Grailles I, et al. Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat 2001;21(3):135-44. (Pubitemid 33109062)
65. Ford C, Morton S, Lintzeris N, Bury J, Gerada C. Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care. 2nd ed. London, UK: RCGP Drug and Alcohol Misuse Training Programme; 2004.
66. Lintzeris N, Clark N, Muhleisen P, Ritter A, Ali R, Bell J, et al. Clinical guidelines: buprenorphine treatment of heroin dependence. Canberra, Australia: Commonwealth of Australia; 2006.
67. Chutuape MA, Silverman K, Stitzer ML. Effects of urine testing frequency on outcome in a methadone take-home contingency program. Drug Alcohol Depend 2001;62(1):69-76. (Pubitemid 32149966)
68. Preston KL, Umbricht A, Epstein DH. Abstinence reinforcement maintenance contingency and one-year follow-up. Drug Alcohol Depend 2002;67(2):125-37. (Pubitemid 34722400)
69. Bell J, Shanahan M, Mutch C, Rea F, Ryan A, Batey R, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007;102(12):1899-907. (Pubitemid 350145664)
70. Perrone J, De Roos F, Jayaraman S, Hollander JE. Drug screening versus history in detection of substance use in ED psychiatric patients. Am J Emerg Med 2001;19(1):49-51. (Pubitemid 32056060)
71. Srivastava A, Kahan M. Buprenorphine: a potential new treatment option for opioid dependence. CMAJ 2006;174(13):1835.